Search the Site


test tubes

$OMER Pair of Phase 3 Results Expected During 2H12

publication date: May 7, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Written by Mike Havrilla -- Omeros (NASDAQ:OMER) is a bio-pharmaceutical company with a late-stage clinical development pipeline based on its PharmacoSurgery platform that is designed to improve the outcomes for surgical procedures such as knee and eye surgery.

Sorry this page is available to subscribers only. 

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:


If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.